

ANALYSIS OF THE MARKET OF ORAL ANTI-DIABETIC MEDICINAL PRODUCTS IN UKRAINE

Berdnik O.G.

Scientific supervisor: Doctor of Pharmacy, Professor Tsubanova N. A.

National University of Pharmacy, Kharkiv, Ukraine

feknfau@ukr.net

Introduction. Over the last 5 years, the prevalence rate of diabetes mellitus (DM) in Ukraine has increased by 6%, and the number of the ill is increasing primarily on account of DM type 2. Nowadays, pharmaceutical market provides a limited assortment of oral anti-diabetic medicinal products (OADMP) for treatment of DM type 2, and low level of availability of complex OADMP, which have a benefit of declining a dosage of an active pharmaceutical ingredient and side effects.

Aim. Study of the assortment, social and economic availability, as well as consumption of OADMP in the Ukrainian pharmaceutical market over the last two years (2015-2016).

Materials and methods. Analysis of the assortment and cost of the medicinal products in the market of Ukraine was conducted based on the data from analytical company “Pharmstandart” of “Morion” company. When analyzing the assortment, the number of manufacturers, variety of product forms, and cost of the package of OADMP were determined over the period of study.

Results and discussion. In 2015, the assortment of OADMP was represented by 148 trade names (TN) based on 18 international nonproprietary names (INN), and in 2016 by 149 TN. Ukrainian market of OADMP is formed of manufacturers from 15 countries, among which a majority is represented by: Ukraine (69 TN), Germany (17 TN), Great Britain (15 TN), Japan (12 TN), the USA (11 TN), Israel (8 TN), and Switzerland (7 TN). All OADMP in the market are represented as 2 pharmaceutical forms: tablets and granules, as well as medicinal products in the form of solution for injections in a pre-filled syringe. Most frequently used form of OADMP is tablets (166 TN). Retail price range for OADMP varies from 10.27 UAH to 5,071.32 UAH. The cheapest OADMP is a product Glibenclamide, Lekhim PJSC (Ukraine), tablets 5 mg, No. 30, and the most expensive one is a medicinal product Victoza®, Novo Nordisk (Denmark), 6 mg / mL, No. 2.

Conclusions. During 2015-2016, minor changes in the assortment of OADMP, provided in the pharmaceutical market of Ukraine, occurred. The number of domestic medicinal products increased, and the number of imported medicinal products reduced, what is considered a positive result, since domestic products are more affordable for consumers. Depending on the manufacturer, prices varied from low to high, which provided a possibility of individual choice of the product, taking into account its active ingredients, pharmaceutical form and price.